Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection CureVac AG Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.